Increased peroxiredoxin 4 levels in patients with prediabetes compared to normal glucose tolerance subjects

Gateva, Antoaneta; Assyov, Yavor; Velikova, Tsvetelina; Kamenov, Zdravko

doi:10.1111/cen.13135

Cited by 8 publications

(5 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, clinically, specific accelerators of PRDX4 may prove useful as therapeutic agents for protecting against the initiation and progression of DM, atherosclerosis, NAFLD, and subsequently metabolic syndrome in humans by suppressing oxidative damage and pro‐apoptotic or inflammatory factors throughout the course of these diseases. By contrast, one paper more recently published has reported that the plasma PRDX4 levels are significantly higher in patients with prediabetes . In line with that, we have also found that patients with type 2 DM show significantly higher serum hPRDX4 levels than healthy adult volunteers, potentially due to the greater demand for antioxidant defense in type 2 DM.…”

Section: Intriguing Topics For Future Studies and Concluding Remarks supporting

confidence: 89%

“…By contrast, one paper more recently published has reported that the plasma PRDX4 levels are significantly higher in patients with prediabetes. 60 In line with that, we have also found that patients with type 2 DM show significantly higher serum hPRDX4 levels than healthy adult volunteers, 8 potentially due to the greater demand for antioxidant defense in type 2 DM. Nevertheless, PRDX4 would have pathophysiological relevance for protecting against metabolic syndrome in humans.…”

Section: Intriguing Topics For Future Studies and Concluding Remarks supporting

confidence: 77%

See 1 more Smart Citation

Peroxiredoxin 4 (PRDX4): Its critical in vivo roles in animal models of metabolic syndrome ranging from atherosclerosis to nonalcoholic fatty liver disease

Yamada

Guo

2018

Pathology International

View full text Add to dashboard Cite

The peroxiredoxin (PRDX) family, a new family of proteins with a pivotal antioxidative function, is ubiquitously synthesized and abundantly identified in various organisms. In contrast to the intracellular localization of other family members (PRDX1/2/3/5/6), PRDX4 is the only known secretory form and protects against oxidative damage by scavenging reactive oxygen species in both the intracellular (especially the endoplasmic reticulum) compartments and the extracellular space. We generated unique human PRDX4 (hPRDX4) transgenic (Tg) mice on a C57BL/6J background and investigated the critical and diverse protective roles of PRDX4 against diabetes mellitus, atherosclerosis, insulin resistance, and nonalcoholic fatty liver disease (NAFLD) as well as evaluated its role in the intestinal function in various animal models. Our published data have shown that PRDX4 helps prevent the progression of metabolic syndrome by reducing local and systemic oxidative stress and synergistically suppressing steatosis, inflammatory reactions, and/or apoptotic activity. These observations suggest that Tg mice may be a useful animal model for studying the relevance of oxidative stress on inflammation and the dysregulation of lipid/bile acid/glucose metabolism upon the progression of human metabolic syndrome, and that specific accelerators of PRDX4 may be useful as therapeutic agents for ameliorating various chronic inflammatory diseases.

show abstract

Section: Intriguing Topics For Future Studies and Concluding Remarks supporting

confidence: 89%

Section: Intriguing Topics For Future Studies and Concluding Remarks supporting

confidence: 77%

Peroxiredoxin 4 (PRDX4): Its critical in vivo roles in animal models of metabolic syndrome ranging from atherosclerosis to nonalcoholic fatty liver disease

Yamada

Guo

2018

Pathology International

View full text Add to dashboard Cite

show abstract

“…According to the previous reports, other PRX members including PRX1, PRX2, PRX4, and PRX6 respond actively to glucose and/or insulin-related oxidative stress [28–30]. In the present study using mouse islet cells, the oxidation of PRX3 was quite fewer as compared to that of PRX1 and/or PRX2 under basal conditions.…”

Section: Discussionsupporting

confidence: 45%

Plasma level of peroxiredoxin 3 in patients with polycystic ovarian syndrome

Liu

et al. 2019

BMC Endocr Disord

View full text Add to dashboard Cite

BackgroundAs a member of peroxiredoxin (PRX) family, PRX3 is predominantly located in mitochondria and plays an important role of free radical scavenging. Since a body of evidence demonstrated the involvement of PRX3 in insulin secretion, insulin sensitivity, and glucose metabolism, the present study was conducted to investigate the role of PRX3 in the pathogenesis of polycystic ovarian syndrome (PCOS) featured in insulin resistance.MethodsEnzyme-linked immunosorbent assay was performed to detect plasma PRX3 in PCOS patients and control subjects. Levels of reactive oxygen species (ROS) and oxidized PRXs were detected in mouse islet cells treated with gradient glucose.ResultsWe did not find significant difference of fasting plasma PRX3 between PCOS patients and controls. No association was noticed between fasting plasma PRX3 and fasting plasma glucose or insulin. After oral glucose tolerance test (OGTT), PCOS patients showed higher levels of both glucose and insulin as compared to controls. The plasma level of PRX3 was significantly increased at 2 h and began to fall back at 3 h of OGTT. There was a one-hour time lag of peak values between plasma PRX3 and insulin, and the plasma PRX3 at 2 h was positively correlated with the insulin level at 1 h of OGTT of PCOS patients. In addition, the level of ROS was significantly elevated at 1 h and oxidized PRX3 was increased dramatically at 2 h of 16.7mM glucose stimulation in mouse islet cells.ConclusionIt seems that PRX3 does not show its antioxidant function under baseline conditions. Instead, PRX3 responds to oxidative stress induced by rapid increase of insulin and glucose in patients with PCOS.

show abstract

“…In contrast, our results showed an association between Prx4 and insulin resistance in PCOS women although we found no association with glucose levels. Differences in the disease type and the number of samples may be the cause of difference in results [ 42 ].…”

Section: Discussionmentioning

confidence: 99%

Association of Prx4, Total Oxidant Status, and Inflammatory Factors with Insulin Resistance in Polycystic Ovary Syndrome

Mazloomi

Sheikh

Farimani

et al. 2021

International Journal of Endocrinology

View full text Add to dashboard Cite

Introduction. Chronic inflammation and oxidative stress conditions have been reported in women with polycystic ovary syndrome (PCOS). Peroxiredoxin 4 (Prx4) is a related antioxidant in insulin synthesis. We hypothesized that insulin resistance in these women is associated with total oxidant status (TOS) and inflammatory factors. Materials and Methods. Two hundred three people including 104 PCOS patients and 99 healthy women, who were matched for age and body mass index (BMI), entered the study. Waist circumference of the participants was measured; serum glucose, lipid profile, insulin, Prx4, TOS, hs-CRP, and TNF-α were also evaluated. Results. The Prx4 level was significantly lower in PCOS than in the control group. In addition, marked increase was observed in the concentration of TOS, hs-CRP, and TNF-α in PCOS, compared to the healthy women. There was a positive correlation of TOS with hs-CRP, TNF-α, and HOMA-IR. The risk of PCOS for subjects with high hs-CRP was 60 times greater than those who had low serum hs-CRP concentration; after performing multiple logistic regression analyses with the backward method, TNF-α was considered as an effective biomarker to predict PCOS β = 49.087 (all p < 0.05 ). Conclusion. This study identified increased oxidative stress and inflammation in PCOS; this may be due to decrease in the antioxidants, such as Prx4.

show abstract

Increased peroxiredoxin 4 levels in patients with prediabetes compared to normal glucose tolerance subjects

Abstract: The levels of peroxiredoxin 4 are higher in patients with prediabetes, but are similar in subjects with and without insulin resistance, which suggests that the main factor for its increased levels is hyperglycaemia and not insulin sensitivity state.

Cited by 8 publications

References 26 publications

Peroxiredoxin 4 (PRDX4): Its critical in vivo roles in animal models of metabolic syndrome ranging from atherosclerosis to nonalcoholic fatty liver disease

Peroxiredoxin 4 (PRDX4): Its critical in vivo roles in animal models of metabolic syndrome ranging from atherosclerosis to nonalcoholic fatty liver disease

Plasma level of peroxiredoxin 3 in patients with polycystic ovarian syndrome

Association of Prx4, Total Oxidant Status, and Inflammatory Factors with Insulin Resistance in Polycystic Ovary Syndrome

Contact Info

Product

Resources

About